Idorsia (OTCMKTS:IDRSF – Get Free Report) is projected to issue its resultson Thursday, July 30th. Analysts expect the company to post earnings of ($0.2412) per share and revenue of $61.2360 million for the quarter.
Idorsia Stock Up 7.8%
OTCMKTS IDRSF opened at $8.19 on Tuesday. Idorsia has a 1-year low of $3.30 and a 1-year high of $8.19. The firm’s fifty day simple moving average is $6.79 and its 200-day simple moving average is $5.35.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Idorsia in a research report on Monday, June 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Idorsia currently has a consensus rating of “Moderate Buy”.
Idorsia Company Profile
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Further Reading
- Five stocks we like better than Idorsia
- Wintrust: A Quiet Regional Bank Posting Loud Results
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
